Target intelligence / Profile preview

Protein phosphatase methylesterase 1 (PPME1)

Target
PPME1
Molecular classification
Enzyme, Protein methylesterase, Carboxylesterase-related protein
01

Overview

Protein phosphatase methylesterase 1 (PPME1) is an enzyme that demethylates proteins—including the catalytic subunit of protein phosphatase 2A (PP2A)—thereby regulating PP2A activity, localization, and function. This demethylation modulates several key signaling pathways, such as the ERK pathway, and is implicated in the regulation of cell proliferation, apoptosis, and tumor progression. PME-1 is highly conserved across eukaryotes and possesses a lipase-like catalytic motif with a serine residue essential for its activity. Elevated PME-1 expression has been linked to various human cancers, with evidence of either oncogenic or tumor suppressor roles depending on the tumor context. PME-1 is considered a therapeutically relevant enzyme, but as of now, no therapies directly target it in clinical settings.

Other names
PME1PME-1PP2593PRO0750ABDH19Testicular secretory protein Li 39
02

Mechanism of action

Okadaic acid: inhibits PME-1 activity, thereby preventing demethylation of PP2A subunit C. Modulators of PME-1 would theoretically alter PP2A activity by affecting the methylation state of its catalytic subunit

03

Biological functions

Regulation of PP2A methylation stateModulation of protein phosphatase 2A (PP2A) activityInhibition/demethylation of PP2A catalytic subunits (PPP2CA, PPP2CB)Cellular signaling (notably ERK pathway)Regulation of cell proliferation, apoptosis, and possibly cell cycle progression
04

Disease associations

Cancer (glioma, endometrial, lung, gastric, and colorectal cancers)Neurodegenerative disease (e.g., associated with Alzheimer disease)Other (potential roles in general tumor biology and signaling disorders)
05

Safety considerations

No clinical safety concerns are currently established due to a lack of selective, approved PME-1-targeting drugs.Potential concerns could stem from altered PP2A activity, which is broadly important for cell regulation and tumor suppression.
06

Interacting drugs

Okadaic acid

1 more in the full profile.

07

Biomarkers

PME-1 expression (potential prognostic or predictive biomarker in cancer, notably colorectal cancer for favorable prognosis; in other cancers, elevated PME-1 correlates with aggressiveness)

Beyond the preview

Go deeper on Protein phosphatase methylesterase 1 (PPME1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein phosphatase methylesterase 1 (PPME1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call